Mustang could pick up another Priority Review voucher

1 September 2020
mustang_bio_large

Mustang Bio (Nasdaq: MBIO) has been awarded Rare Pediatric Disease designation for MB-207 from the US Food and Drug Administration.

The firm is focused on cell and gene therapies to treat hematologic cancers, solid tumors and rare genetic diseases.

MB-207 is a lentiviral gene therapy for the treatment of certain people with X-linked severe combined immunodeficiency (XSCID), also known as bubble boy disease.

The firm, which  already received the designation for people with newly diagnosed XSCID, is also developing MB-207 for people who have been treated with a hematopoietic stem cell transplantation (HSCT), without success.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology